Ablynx has announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company`s forthcoming Special General Meeting of its shareholders to be held on 18 August 2017.
Windels is currently CEO ad interim of Biocartis NV and a member of the Board of Biocartis NV, Biocartis Group NV, Erytech Pharma SA and Vlaams Instituut voor Biotechnologie (VIB).
Welcoming Windels to the Ablynx Board, Dr Peter Fellner, Chairman, said: “We are very pleased with the proposed forthcoming appointment of Hilde Windels to the Ablynx Board. Hilde`s broad industry experience as well as her impressive financial expertise will help guide the Company as we continue to build value in terms of both our proprietary product pipeline and strategic collaborations with pharmaceutical companies using our Nanobody platform.”
Commenting on her appointment, Windels added: “I am delighted to become part of Ablynx`s Board and contribute to the Company`s future development. Ablynx has ambitions to become a vertically integrated pharmaceutical company and I look forward to contributing to this exciting journey.”